NAVB — Navidea Biopharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.07m
- -$2.25m
- $0.07m
Annual cashflow statement for Navidea Biopharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -16.1 | -10.9 | -10.7 | -11.7 | -15.2 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 6.4 | 0.327 | 0.638 | 0.489 | 0.977 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 13.8 | 1.12 | 1.84 | 0.947 | 5.12 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 4.28 | -9.35 | -8.17 | -10.2 | -8.99 |
| Capital Expenditures | -0.046 | -0.03 | -0.414 | -0.329 | -0.39 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 1 | 0.8 | 0.001 | 0 | — |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 0.954 | 0.77 | -0.413 | -0.329 | -0.39 |
| Financing Cash Flow Items | -7.15 | 0 | -0.205 | -0.087 | -1.01 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -4.55 | 6.16 | 10.2 | 12.1 | 7.14 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.681 | -2.43 | 1.62 | 1.56 | -2.24 |